| Today's News |
|---|
2 hours ago.
 |
Course aims to inform providers about drug abuse
New River Valley Current - Christiansburg,VA,United States
By Sarah Bruyn Jones As the number of Virginians dying from prescription drug overdoses has soared, the medical community wants to better educate providers about drug seekers. From 2006 to 2010, deaths from prescription drugs jumped 39 percent, ... [more]
 |
| |
|
2 hours ago.
|
Maryland restores money for biotechs, stem cell research fund
Business Gazette - Gaithersburg,MD,USA
Legislators restored funding for the biotechnology investment tax credit program and stem cell research fund, to the relief of advocates for those programs. “Those are two important programs for Maryland companies and institutions,” said Marty Zug, . [more]
|
4 hours ago.
|
Pitt Researchers Develop Synthetic Platform to Produce Materials for
Materials Views
Materials Views (blog) Despite significant advances, the development of synthetic biomaterials still presents a great challenge to biomedical engineering researchers. Although synthetic biodegradable materials such as polyester exist, most are biolog [more]
|
4 hours ago.
|
Paralyzed Taunton woman moves robotic arm
WHDH-TV - Boston,MA,USA
BOSTON (WHDH) -- A medical breakthrough that was partially developed in Boston is giving a local woman a helping hand, and drawing international attention. The robotic arm is controlled by a patient's thoughts, and is changing the life a Taunton woma [more]
|
5 hours ago.
|
Bernstein Liebhard LLP Reports On Upcoming FDA Meeting Seeking Input
San Francisco Chronicle - San Francisco,CA,USA
San Francisco Chronicle (press release) Bernstein Liebhard LLP reports on the inaugural FDA Patient Network Annual Meeting to be held on May 18, 2012. The meeting will allow patients and advocates to discuss and review FDA drug and medical device reg [more]
|
5 hours ago.
|
A Stem-Cell-Based Drug Gets Approval in Canada
New York Times - New York,NY,USA
In a boost for the field of regenerative medicine, a small biotechnology company has received regulatory approval in Canada for what it says is the first manufactured drug based on stem cells. The company, Osiris Therapeutics of Columbia, Md., ... [more]
|
5 hours ago.
|
World's First Approved Stem Cell Drug; Osiris Receives Marketing
Biloxi Sun Herald - Biloxi,MS,USA
SunHerald.com COLUMBIA, Md. -- Osiris Therapeutics Inc. (NASDAQ: OSIR) announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host diseas [more]
|
5 hours ago.
|
Canada OKs Osiris drug; first stem cell therapy
MSN Money
By Toni Clarke BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic . [more]
|
7 hours ago.
|
TVAX Biomedical Requests Withdrawal Of IPO, Cites Market Conditions
Wall Street Journal - USA
TVI-Brain is intended to treat astrocytoma, a type of glioma, in conjunction with surgery. Glioma, a broad category of brain and spinal-cord tumors, is the most prevalent form of brain cancer. Like many development-stage companies, TVAX Biomedical ha [more]
|
7 hours ago.
|
State Awards Stem Cell Research Funding
Citybizlist (press release)
By Nick Sohr, Managing Editor, MDBIZNews Maryland approved state funding for 40 researchers studying human stem cells and their applications in treating a wide range of diseases and other medical conditions. The awards, approved Thursday by the ... [more]
|
| Last 10 Articles (Prior to Today)
|
Thursday, May 17
|
MarketWatch - USA
MarketWatch (press release) The Company is focusing on increasing sales of its Calmare(R) medical device with "Scrambler Therapy"(TM) technology. To accomplish this goal, it has developed a three-point strategy which it began implementing during the [more]
|
Thursday, May 17
|
CBS News - USA
NEW YORK — Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants. The company said Health Canada approved Prochymal for use [more]
|
Thursday, May 17
|
Investigation
Researchers in Singapore have uncovered new technology for studying cancer stem cells that could spark quicker development of a more effective therapy to fight mesothelioma. The findings came from the Institute of Bioengineering and Nanatechnology an [more]
|
Thursday, May 17
|
University at Buffalo Reporter - Buffalo,NY,USA
This year's recipient is Mark Lema, professor and chair of the Department of Anesthesiology, School of Medicine and Biomedical Sciences. The Chancellor's Award for Excellence in Teaching honors those who consistently demonstrate superb teaching at th [more]
|
Thursday, May 17
|
Greenfield Daily Reporter - IN, USA
Medical device maker Boston Scientific Corp. said Thursday it received US approval for a new type of stent to treat blocked arteries in the legs. The Food and Drug Administration approved the company's Epic Vascular Self-Expanding stent for iliac ... [more]
|
Thursday, May 17
|
Manufacturers
InjuryBoard.com The DePuy ASR hip recall initiated in August of 2010 has been a hot topic of discussion in the medical community over the last year and half. Surprisingly thousands of patients are still unaware of the detailed history and circumstanc [more]
|
Thursday, May 17
|
CBC News - Canada
Why is it that so much scientific research ends up making headlines? Because they ask us to report on their research, that's one reason. Medical journals and research institutions work hard to make sure that their scientific papers appear in the news [more]
|
Thursday, May 17
|
Washington Post
Nancy Dawson is director of clinical research at the Prostate Cancer Research and Treatment Center, a subsidiary of the larger Georgetown Lombardi Comprehensive Cancer Center. At Georgetown, she continues to develop innovative approaches to treating [more]
|
Thursday, May 17
|
MarketWatch - USA
The net loss of $0.13 per share in the quarter was primarily a result of the Company's continued investment in WirelessDx, our start-up medical services subsidiary. R&D expenses related to FDA device clearance efforts and updates to ART's customizabl [more]
|
Thursday, May 17
|
Healthcanal.com
“This is the first time that breakthrough (chemotherapy-induced nausea and vomiting) has been studied in a systematic way,” said Rudolph M. Navari, MD, Ph.D., lead author of the study and professor of medicine, associate dean of Indiana University .. [more]
|
